ViiV pulls once-daily maraviroc submissions
This article was originally published in Scrip
ViiV Healthcare, the HIV-focused joint venture between GlaxoSmithKline and Pfizer, has withdrawn its Type II Variation to the European Medicines Agency (EMA) and its supplemental new drug application (sNDA) to the US FDA for once-daily administration of Celsentri/Selzentry (maraviroc) tablets in treatment-experienced patients infected with only CCR5-tropic HIV-1.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.